[Remote] Director / Senior Director, Clinical Development Scientist at Abata Therapeutics

Remote

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, HealthcareIndustries

Skills

Key technologies and capabilities for this role

Clinical DevelopmentPhase III trialsProtocol DevelopmentRegulatory StrategyBiostatisticsClinical OperationsSafetyMonoclonal AntibodiesNeurological Disease

Questions & Answers

Common questions about this position

Is remote work allowed for this position?

Yes, the company is open to you working remotely.

What education is required for this role?

An advanced degree in life/health sciences such as PhD, PharmD, MD, MPH or equivalent is required.

What experience is essential for success in this role?

You must have experience supporting global phase III trials to be successful in this role.

What is the company culture like?

The company is building a culture of individuals who hold our core principles at the center of our operations, with the goal to elevate the care of our patients’ lives.

What makes a strong candidate for this position?

A strong candidate will have experience leading the scientific aspects of global Phase III pivotal trials, including protocol development, regulatory strategy, and cross-functional collaboration.

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free